Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-12
1998-08-18
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514912, A61K 31355
Patent
active
057959129
ABSTRACT:
This invention provides a therapeutic composition for corneal impairment which comprises a phosphoric acid diester compound of the following formula or a pharmacologically acceptable salt thereof, ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represents a hydrogen atom or a methyl group.
The therapeutic composition of this invention is useful for the treatment of electricity-related ophthalmia, snow-related ophthalmia, corneal lesions caused by contact lens wearing, and corneal impairment associated with hypolacrimia.
REFERENCES:
Shimoyama et al., Investigative Ophthalmology & Visual Science, vol. 36, No. 4 15 Mar. 1995 p. 5696.
Senju Pharmaceutical, Database WPI Week 9201, Derwent Publications, Ltd., London GB AN 92-002618 JP-A-03 255 026 13 Nov. 1991.
Lazarenko et al., STN File Supplied: Chemical Abstracts AN = 85:91566.
Neuwirth-Lux et al., Australian and New Zealand Journal of Ophthalmology, vol. 15, pp. 309-314.
Saika et al., Graefe's Archive for Clinical and Experimental ophthalmology, vol. 231 (1993) pp. 221-227.
Fay Zohreh
Senju Pharmaceutical Co. Ltd.
LandOfFree
Therapeutic composition for corneal impairment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic composition for corneal impairment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic composition for corneal impairment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1115124